Publications
5600 Results
- Journal / Conference
- JAMA Oncology Nov 1;2(11):1511
- Year
- 2016
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID: 27355398
- PMC
- PMC n/a - Correspondence
Measuring the real clinical impact of randomized clinical trials in oncology-reply: beyond citation counts [Comment and Response]
- Journal / Conference
- JAMA Surgery Jun 8:e161137
- Year
- 2016
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID27275632
- PMC
- PMC5210022
- Study Number(s)
- CTSU/A021101
Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101
- Journal / Conference
- Journal of Geriatric Oncology 2016 Jul 25. pii: S1879-4068(16)30088-1. doi: 10.1016/j.jgo.2016.07.002 Jul 25 [Epub ahead of print]
- Year
- 2016
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID27468630
- PMC
- PMC5159186
- Study Number(s)
- SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database
- Journal / Conference
- New England Journal of Medicine Jul 21;375(3):209-219
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID27264120
- PMC
- PMC5024713
- Study Number(s)
- JMA17
Extending aromatase-inhibitor adjuvant therapy to 10 years
- Journal / Conference
- American Journal of Hematology Mar;91(3):308-312
- Year
- 2016
- Research Committee(s)
- Leukemia
- PMID
- PMID26662208
- PMC
- PMC4806550
- Study Number(s)
- CTSU/E1908
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)
- Journal / Conference
- Journal of Clinical Oncology 34, 2016 (suppl 26S; abstr 44); ASCO Palliative Care in Oncology Symposium (Sept 9-10, 2016, San Francisco, CA), poster
- Year
- 2016
- Research Committee(s)
- Cancer Care Delivery
Usage of Oregon’s Death with Dignity Act (DWDA)
- Journal / Conference
- Blood 128:616;American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
- Year
- 2016
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0016
Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus rituximab or CHOP plus (131) iodine-tositumomab - long term follow-up of phase III randomized study SWOG S0016
- Journal / Conference
- Blood 128:896; American Society of Hematology Annual Meeting(December 3-6, 2016, San Diego, CA), oral
- Year
- 2016
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0535
ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): final results of the SWOG/Alliance/ECOG S0535 trial
- Journal / Conference
- Blood 128:614; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral presentation
- Year
- 2016
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0801
Sequential RCHOP, radioimmunotherapy and rituximab maintenance improves early outcomes in advanced stage follicular lymphoma: 5 year outcomes from SWOG 0801 [http://www.bloodjournal.org/content/128/22/614]
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 6-10, 2016, San Antonio, TX), oral
- Year
- 2016
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S1202